ResearcherKagawa UniversityActive in the last 2 years
Toru Shibata
Matched on ORCID iD 0000-0002-5972-1262; OpenAlex author ID A5078435301. Sources: OpenAlex.
Their work
- Papers
- 13 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 2 papers
Papers 13
- A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectabl… Co-author DOI 10.1245/s10434-025-18714-7↗
- ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and… Co-author DOI 10.1245/s10434-025-18894-2↗
- Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emission tomography in patients with resectabl… Co-author DOI 10.1016/j.pan.2024.08.010↗
- Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients with Resectable and Borderline Resectable … Co-author DOI 10.3390/jcm13051216↗
- Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adeno… Co-author DOI 10.1016/j.hpb.2022.10.004↗
- Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiothe… Co-author DOI 10.1002/jso.26854↗
- Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002011↗
- Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable p… Co-author DOI 10.1186/s12876-020-01566-8↗
- Is surgery after neoadjuvant chemoradiotherapy feasible for elderly patients with resectable or borderline resectable pancreatic ductal adenocarcinoma? Co-author DOI 10.21203/rs.2.21112/v1↗
- Differences in gross tumor volumes for pancreatic cancer: a comparison of ungated positron emission tomography and contrast-enhanced four-dimensional computed … Last author DOI 10.1007/s11604-019-00812-8↗
- The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvan… Co-author DOI 10.1186/s12893-019-0644-z↗
- Respiratory motion of lymph node stations in pancreatic cancer: Analyses using contrast-enhanced four-dimensional computed tomography. Last author DOI 10.1016/j.radonc.2018.05.007↗
- A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic … Co-author DOI 10.1245/s10434-017-5921-4↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hironobu Suto · 11 shared papers, 2017–2026 · strength 1.74
- Paper A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy… DOI 10.1245/s10434-025-18714-7↗
- Paper ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofrac… DOI 10.1245/s10434-025-18894-2↗
- Paper Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emissi… DOI 10.1016/j.pan.2024.08.010↗
- Minoru Oshima · 11 shared papers, 2017–2026 · strength 1.74
- Paper A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy… DOI 10.1245/s10434-025-18714-7↗
- Paper ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofrac… DOI 10.1245/s10434-025-18894-2↗
- Paper Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emissi… DOI 10.1016/j.pan.2024.08.010↗
- Keiichi Okano · 11 shared papers, 2017–2026 · strength 1.74
- Paper A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy… DOI 10.1245/s10434-025-18714-7↗
- Paper ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofrac… DOI 10.1245/s10434-025-18894-2↗
- Paper Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emissi… DOI 10.1016/j.pan.2024.08.010↗
- Shigeo Takahashi · 10 shared papers, 2017–2024 · strength 1.34
- Paper Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emissi… DOI 10.1016/j.pan.2024.08.010↗
- Paper Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients wi… DOI 10.3390/jcm13051216↗
- Paper Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borde… DOI 10.1016/j.hpb.2022.10.004↗
- Tsutomu Masaki · 7 shared papers, 2017–2023 · strength 0.83
- Paper Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borde… DOI 10.1016/j.hpb.2022.10.004↗
- Paper Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative r… DOI 10.1002/jso.26854↗
- Paper Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderli… DOI 10.1097/mpa.0000000000002011↗
- Yasuyuki Suzuki · 7 shared papers, 2017–2023 · strength 0.83
- Paper Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borde… DOI 10.1016/j.hpb.2022.10.004↗
- Paper Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative r… DOI 10.1002/jso.26854↗
- Paper Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderli… DOI 10.1097/mpa.0000000000002011↗
- Akihito Tsuji · 3 shared papers, 2022–2026 · strength 0.68
- Paper A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy… DOI 10.1245/s10434-025-18714-7↗
- Paper ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofrac… DOI 10.1245/s10434-025-18894-2↗
- Paper Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderli… DOI 10.1097/mpa.0000000000002011↗
- Mina Nagao · 2 shared papers, 2024 · strength 0.37
- Paper Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emissi… DOI 10.1016/j.pan.2024.08.010↗
- Paper Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients wi… DOI 10.3390/jcm13051216↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.